No products in the cart.
Return To ShopNo products in the cart.
Return To ShopNo products in the cart.
Return To Shopanabolicdirectplus.com
No products in the cart.
Return To ShopBeligas Pharma Mono- Femara, containing Letrozole at a dosage of 2.5mg, is an aromatase inhibitor primarily formulated to manage specific types of breast cancer in postmenopausal women. By inhibiting the aromatase enzyme, Letrozole effectively reduces estrogen production in the body, thereby slowing down or stopping the growth of hormone-dependent tumors. While its primary application lies within oncology, Letrozole has gained popularity among athletes and bodybuilders looking to manipulate hormonal balance, particularly during bulking and cutting cycles.
Letrozole works by blocking the conversion of androgens into estrogens, which can significantly alter the way the body processes hormones. This effect is particularly prominent in male users who may be prone to estrogen-related side effects, such as gynecomastia. Athletes often utilize this compound not only to avoid these side effects but also to potentially enhance muscle definition, vascularity, and overall performance during intense training regimes.
The use of Beligas Pharma Mono- Femara (Letrozole 2.5mg) among athletes and bodybuilders provides several key advantages. These benefits extend beyond its primary use in treating cancer, making it a versatile tool in the realm of sports pharmacology.
1. Gynecomastia Prevention: One of the most critical benefits for male athletes is the prevention of gynecomastia, a condition characterized by the enlargement of breast tissue. By inhibiting estrogen production, Letrozole helps maintain a more favorable testosterone to estrogen ratio.
2. Improved Lean Muscle Mass: Athletes often seek to optimize their body composition. Letrozole’s capability to manage estrogen levels allows users to attain a leaner physique, making muscle gains more prominent without the added water retention often associated with high estrogen levels.
3. Increased Vascularity: With lower estrogen levels, users frequently report improved vascularity. Enhanced blood flow and visibility of veins are not just aesthetic pursuits but can also reflect improvements in muscle pump and endurance during workouts.
4. Post-Cycle Therapy: After a cycle of anabolic steroids, hormone levels often become imbalanced. Letrozole is sometimes used as part of a post-cycle therapy (PCT) plan to help restore natural testosterone production while minimizing estrogen-related side effects.
5. Energy and Endurance: By possibly enhancing metabolic rates due to hormonal balance, athletes can experience increased energy levels and overall stamina during training sessions.
For those interested in purchasing Beligas Pharma Mono- Femara (Letrozole 2.5mg), it is crucial to acquire it from verified and reputable sources to ensure quality and authenticity. Look for certified online pharmacies or health supplement stores that specifically list this product. Additionally, reviewing customer feedback and product ratings can guide you in making a safe purchase. Websites that require prescriptions may offer additional guarantees regarding the legitimacy of their products. Always prioritize your health by avoiding unauthorized or black-market suppliers, as they may provide counterfeit or unsafe alternatives.
While Beligas Pharma Mono- Femara can have significant benefits, it is not suitable for everyone. Certain populations should avoid its use to mitigate potential health risks.
Individuals who should refrain from using Letrozole include:
1. Those with hypersensitivity or allergic reactions to Letrozole or any component of the formulation.
2. Pregnant or breastfeeding women, as the drug can potentially harm the fetus or nursing infant.
3. Individuals with severe liver impairment or any liver diseases, as Letrozole is metabolized by the liver and could exacerbate existing conditions.
4. Pre-menopausal women, as the intended hormonal modulation may not be appropriate for those who still produce significant levels of estrogen.
5. Individuals on medications that may interact negatively with Letrozole, such as other hormone therapies or certain antifungal and antiviral medications.
Always consult with a healthcare provider before initiating any new medications or supplementation, especially if you have underlying health conditions.
The recommended dosage of Beligas Pharma Mono- Femara for those utilizing it within a sports context may vary based on individual goals, previous experience, and the overall regimen in place. However, general dosing guidelines suggest:
1. Typical daily dose: 2.5mg taken once daily, preferably at the same time to maintain consistency.
2. Duration of treatment:
As with any potent compound, careful management and adherence to recommended guidelines are essential for maximizing benefits while minimizing risks.
| Active substance | LETROZOLE 2.5 |
|---|---|
| Active Half-Life | 9 hours |
| Classification | ANTI ESTROGEN |
| Acne | NONE |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | Low |
| Aromatization | No |
| Lab Test | Monitoring of blood estrogen levels and liver function tests |
| Also known as | Letrozole |
| DOSAGE MEN | 2.5/DAY |
| DOSAGE WOMEN | 2.5/DAY |
| Blood pressure | May cause a decrease |
| Trade name | Femara |
| Tab Piece | 50 COUNTS |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | Letrozole |
| Formula | C17H11N5 |
| Substance class | Aromatase inhibitor |
| Main action | Inhibits the enzyme aromatase, which is involved in estrogen synthesis |
| Half-life | Approximately 2 days |
| Dosage (medical) | 2.5 mg once daily |
| Dosage (sports) | 1.25 mg to 2.5 mg every other day |
| Effects | Reduces estrogen levels, increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) |
| Side effects | Hot flashes, joint pain, fatigue, risk of osteoporosis |
| Use in sports | Used to counteract the side effects of estrogen produced by aromatizing anabolic steroids |
Select at least 2 products
to compare
Reviews
There are no reviews yet.